scholarly journals Observation of Efficacy of Internet-Based Chronic Disease Management Model Combined with Modified Therapy of Bushenyiliu Decoction in Treating Patients with Type 2 Diabetes Mellitus and Prostate Cancer and Its Effect on Disease Control Rate

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Yi Wang ◽  
Ankang Yin ◽  
Tingting Bian ◽  
Xiangyu Zhao ◽  
Shijun Zheng ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Chronic Disease ◽  
Disease Management ◽  
Chronic Disease Management ◽  
Management Model ◽  
Control Group ◽  
Experimental Group

Objective. To explore the efficacy of Internet-based chronic disease management model combined with the modified therapy of Bushenyiliu decoction in treating patients with type 2 diabetes mellitus (T2DM) and prostate cancer and its effect on disease control rate (DCR). Methods. 120 patients with T2DM and prostate cancer admitted to the Affiliated Hospital of Yangzhou University, Yangzhou First People’s Hospital, from February 2019 to February 2020, were retrospectively analyzed and equally divided into the experimental group and the control group according to their admission order. Conventional treatment combined with the modified therapy of Bushenyiliu decoction was performed on all patients for 3 months, and the Internet-based chronic disease management model was adopted for patients in the experimental group additionally, so as to compare their short-term effect, survival time, disease progression, blood glucose indicators, immune function indicators, and type 2 Diabetes Self-Care Scale (2-DSCS) scores. Results. Compared with the control group, the experimental group obtained significantly higher DCR and objective remission rate (ORR) ( P < 0.05 ), higher survival time and disease progression ( P < 0.001 ), better blood glucose indicators and immune function indicators ( P < 0.001 ), and higher 2-DSCS scores ( P < 0.001 ) after treatment. Conclusion. Combining the Internet-based chronic disease management model with the modified therapy of Bushenyiliu decoction can effectively enhance the self-care ability of patients with T2DM and prostate cancer, improve their blood glucose level, promote their body immunity, and comprehensively optimize the cancer control effect, which should be promoted in practice.

scholarly journals Effects of Fasting-Mimicking Diet and Specific Meal Replacement Foods on Blood Glucose Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Fang Tang ◽  
Xuan Lin
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Venous Blood ◽  
Fasting Blood Glucose ◽  
Blood Glucose Control ◽  
Density Lipoprotein ◽  
Control Group ◽  
Meal Replacement ◽  
Experimental Group

Type 2 diabetes represents a serious societal health problem due to the vulnerability to cardiovascular events. Diet therapy is the most basic treatment for type 2 diabetes. The present study was conducted to study the effect of a fasting-mimicking diet and specific meal replacement foods on blood glucose control in patients with type 2 diabetes. Our study included 100 patients with type 2 diabetes who underwent a physical examination which were enrolled and randomly assigned as 50 patients each to the test group (with low energy-specific meal replacement meals during a fasting-mimicking diet) and the control group (with specific meal replacement foods given normal adult doses). After 4 months, efficacy indicators which were fasting blood glucose, 2-hour postprandial venous blood glucose, and glycosylated haemoglobin of the experimental group were all lower than those of the control group ( P < 0.05 ); observation indicators that include body mass index, waist circumference, blood lipids (triglyceride, cholesterol, and low-density lipoprotein), and blood pressure levels were all lower than the control group, and high-density lipoprotein levels were all higher than the control group (all P < 0.05 ). Both groups of fasting blood glucose, 2-hour postprandial venous blood glucose, and blood pressure had a relatively stable downward trend, but the experimental group had a more significant decline. In conclusion, the study revealed that a fasting-mimicking diet and specific meal replacement foods can safely and effectively reduce weight and improve metabolic syndrome in patients with type 2 diabetes.

scholarly journals A Personalized Mobile Health Program for Type 2 Diabetes During the COVID-19 Pandemic: Single-Group Pre–Post Study (Preprint)

2020 ◽  
Author(s):  
Ian Yi Han Ang ◽  
Kyle Xin Quan Tan ◽  
Clive Tan ◽  
Chiew Hoon Tan ◽  
James Wei Ming Kwek ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Disease ◽  
Disease Management ◽  
Mobile Health ◽  
Intervention Program ◽  
Chronic Disease Management ◽  
Diabetes Management ◽  
Mobile App ◽  
Diabetes Status

BACKGROUND With increasing type 2 diabetes prevalence, there is a need for effective programs that support diabetes management and improve type 2 diabetes outcomes. Mobile health (mHealth) interventions have shown promising results. With advances in wearable sensors and improved integration, mHealth programs could become more accessible and personalized. OBJECTIVE The study aimed to evaluate the feasibility, acceptability, and effectiveness of a personalized mHealth-anchored intervention program in improving glycemic control and enhancing care experience in diabetes management. The program was coincidentally implemented during the national-level lockdown for COVID-19 in Singapore, allowing for a timely study of the use of mHealth for chronic disease management. METHODS Patients with type 2 diabetes or prediabetes were enrolled from the Singapore Armed Forces and offered a 3-month intervention program in addition to the usual care they received. The program was standardized to include (1) in-person initial consultation with a clinical dietitian; (2) in-person review with a diabetes specialist doctor; (3) 1 continuous glucose monitoring device; (4) access to the mobile app for dietary intake and physical activity tracking, and communication via messaging with the dietitian and doctor; and (5) context-sensitive digital health coaching over the mobile app. Medical support was rendered to the patients on an as-needed basis when they required advice on adjustment of medications. Measurements of weight, height, and glycated hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) were conducted at 2 in-person visits at the start and end of the program. At the end of the program, patients were asked to complete a short acceptability feedback survey to understand the motivation for joining the program, their satisfaction, and suggestions for improvement. RESULTS Over a 4-week recruitment period, 130 individuals were screened, the enrollment target of 30 patients was met, and 21 patients completed the program and were included in the final analyses; 9 patients were lost to follow-up (full data were not available for the final analyses). There were no differences in the baseline characteristics between patients who were included and excluded from the final analyses (age category: <i>P</i>=.23; gender: <i>P</i>=.21; ethnicity: <i>P</i>&gt;.99; diabetes status category: <i>P</i>=.52, medication adjustment category: <i>P</i>=.65; HbA<sub>1c</sub> category: <i>P</i>=.69; BMI: <i>P</i>&gt;.99). The 21 patients who completed the study rated a mean of 9.0 out of 10 on the Likert scale for both satisfaction questions. For the Yes-No question on benefit of the program, all of the patients selected “Yes.” Mean HbA<sub>1c</sub> decreased from 7.6% to 7.0% (<i>P</i>=.004). There were no severe hypoglycemia events (glucose level &lt;3.0 mmol/L) reported. Mean weight decreased from 76.8 kg to 73.9 kg (<i>P</i>&lt;.001), a mean decrease of 3.5% from baseline weight. Mean BMI decreased from 27.8 kg/m<sup>2</sup> to 26.7 kg/m<sup>2</sup> (<i>P</i>&lt;.001). CONCLUSIONS The personalized mHealth program was feasible, acceptable, and produced significant reductions in HbA<sub>1c</sub> (<i>P</i>=.004) and body weight (<i>P</i>&lt;.001) in individuals with type 2 diabetes. Such mHealth programs could overcome challenges posed to chronic disease management by COVID-19, including disruptions to in-person health care access. CLINICALTRIAL

For Physical Laborers with Type 2 Diabetes, Telephonic Health Coaching is not Enough to Improve A1C

2019 ◽  
Vol 16 (1) ◽  
pp. 80-83
Author(s):  
Mike Swoboda
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Disease ◽  
Disease Management ◽  
Test Group ◽  
Health Coaching ◽  
Control Group ◽  
Haemoglobin A1c ◽  
Eligibility Criteria ◽  
Current Form

Objectives: Telephonic health coaching has been studied extensively as an interventional approach for chronic disease management. No studies have been conducted evaluating the outcomes of a multiyear study on health coaching participation and glycated haemoglobin (A1C) changes. Chronic disease has been widespread in physical laborers, with a high onset of type 2 diabetes. The purpose of this study was to establish the efficacy of telephonic health coaching as a means to manage type 2 diabetes in adults with physical labor occupations. Methods: The eligibility criteria were: 1) Adults aged 20-80 during the study entirety; 2) A diagnosis of type 2 diabetes; and 3) Yearly A1C and Body Mass Index (BMI) testing via verified biometric screenings. Participants completing health coaching for at least 2 years during the study period were assigned to the experimental group and participants who only had yearly biometric screening were assigned to the control group. Results: From 2014-2018, 350 participants met the inclusion criteria. The mean age at baseline was 56 years (SD 8.26), with a mean baseline A1C of 7.14% for the test group, and 5.41% for the control group. Pre-post test changes saw an increase in A1C of 0.85% in the test group, and 0.95% in the control group. BMI changes were not statistically significant. Conclusions: Further study is needed to refine current telephonic health coaching programs for disease management. This study suggests that the efficacy of telephonic health coaching in its current form is not enough to improve BMI outcomes in patients with diabetes, and over the phone coaching alone is insufficient to improve patient A1C levels and sustain them for long-term.

scholarly journals EFFECT OF SGLT-2 INHIBITOR ON BONE TURNOVER IN OVERWEIGHT AND OBESE PATIENTS WITH TYPE 2 DIABETES

2021 ◽  
Author(s):  
WEN-TAO LV ◽  
QIU-MEI ZHANG ◽  
XIANG-WEN MENG
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Bone Turnover ◽  
Hypoglycemic Agents ◽  
Control Group ◽  
Obese Patients ◽  
Oral Hypoglycemic Agents ◽  
Significant Difference ◽  
Experimental Group

To investigate the effect of sodium glucose cotransporter 2 inhibitor (SGLT-2I) on bone turnover markers in overweight and obese patients with type 2 diabetes mellitus. Methods: according to the criteria of selection and exclusion, 42 patients with overweight and obese type 2 diabetes (BMI≥25kg/m2) were selected from October 2019 to May 2020. The patients were randomly divided into experimental group and control group, there were 18 cases in the experimental group and 24 cases in the control group. The experimental group was treated with SGLT-2I, and other oral hypoglycemic agents (or insulin) were added according to the blood glucose situation. The control group received oral hypoglycemic agents (non-SGLT-2I) and/or insulin and/or glucagon-like peptide-1 receptor agonist (GLP-1 RA). Every 28 days of follow-up, medication regimen was adjusted according to blood glucose and adverse reactions of patients. Fasting venous serum of the patients was collected at the beginning and again 24 weeks later and the levels of PINP and β-CTX were detected uniformly. SPSS 21.0 was used to compare the changes of clinical indexes before and after the treatment. Results: 1. In the experimental group, PINP, HbA1c, FPG and BMI decreased (p<0.05). 2. In the control group, HbA1c, FPG and PINP decreased (p<0.05). 3. Comparison between groups after 24 weeks of treatment: there was significant difference in BMI (p<0.05).

scholarly journals Analysis of community chronic disease health management mode under the background of big data

2021 ◽  
Vol 275 ◽  
pp. 02026
Author(s):  
Zehao Yao ◽  
Shihua Cao
Keyword(s):  
Big Data ◽  
Blood Glucose ◽  
Chronic Disease ◽  
Disease Management ◽  
Real Time ◽  
Chronic Disease Management ◽  
Diagnosis And Treatment ◽  
Management Model ◽  
Diabetic Patients ◽  
Hospital Doctors

In recent years, the “Internet + medical” exploration and the country’s vigorously promoted hierarchical diagnosis and treatment system have provided an opportunity to improve the status quo of diabetes. Some scholars have proposed “one-to-one binding community nurses” (Wang Li et al., 2016) and personalized treatment based on big data (He Ting et al., 2016). New chronic disease management concepts such as an integrated chronic disease management model for the elderly based on mobile medical technology (Che Fengyuan et al., 2016). Although different names are used, the core point of view is that patients and community doctors complete the contract, the community doctors will take care of the patients, and the hospital doctors will take care of the patients. The patient’s blood glucose data can be shared with relatives and friends, community doctors, and hospital doctors in real time with the help of platform tools such as blood glucose meters, mobile apps, and cloud medical platforms. And community and hospital doctors’ feedback on patients can also be sent to patients and relatives and friends in real time, thereby realizing hierarchical diagnosis and treatment of diabetic patients when medical resources are scarce and unevenly distributed. This article refers to this model as the “family-style chronic disease management model”. The interaction between patients, relatives and friends, community doctors, and hospital doctors is shown in Figure 1.

scholarly journals Health professionals’ views of the first national GP payment scheme for structured type 2 diabetes care in Ireland: a qualitative study

2021 ◽  
Vol 4 ◽  
pp. 128
Author(s):  
Niamh McGrath ◽  
Fiona Riordan ◽  
Patricia M Kearney ◽  
Kate O'Neill ◽  
Sheena M McHugh
Keyword(s):  
Type 2 Diabetes ◽  
General Practice ◽  
Chronic Disease ◽  
Disease Management ◽  
Health Professionals ◽  
Chronic Disease Management ◽  
Diabetes Management ◽  
Payment Scheme ◽  
Payment Schemes

Background: Payment schemes are widely used to improve chronic disease management in general practice. Although stakeholder views of such schemes could provide valuable learning regarding aspects that work and those which are more difficult to implement, there is a paucity of such data. We explored health professionals’ views of the implementation of the first national general practice payment scheme for type 2 diabetes (T2DM) care in Ireland, the ‘cycle of care’. Methods: Qualitative data were drawn from a multiple case study evaluating the implementation of a National Clinical Programme for Diabetes, collected from April 2016 to June 2017. Interview and focus group transcripts from participants involved in providing diabetes management in general practice and who referenced the cycle of care were eligible for inclusion in the current analysis. Data were analysed using reflective thematic analysis. Results: We analysed data from 28 participants comprising general practitioners (GPs) (n=8), practice nurses (n=9) and diabetes nurse specialists (DNS) (n=11). Participants perceived the cycle of care as “not adequate, but…a good start” to improve T2DM care in general practice in Ireland. Perceived benefits were greater financial viability for T2DM management in general practice, fostering a more proactive approach to T2DM care, delivery of T2DM care closer to patients’ homes, and increased use of other community diabetes services e.g., DNS and podiatry. Participants identified the limited resource for practice nurse time, inflexibility to provide care based on patient need and issues with data submission as drawbacks of the cycle of care. Conclusions: The cycle of care was viewed as a positive first step to increase and improve T2DM care delivered in general practice in Ireland. The implementation issues identified in this study should be considered in the design of future payment schemes targeting chronic disease management in general practice.

Sign in / Sign up

Export Citation Format

Share Document